Science

Mar 2, 2025, 10:50

Myeloma Paper of the Day, March 2nd, suggested by Robert Orlowski

Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: Retrospective study of salvage treatments after covalent BTKi failure in Waldenstrom macroglobulinemia patients finds PFS of 5.8, 5.0, 6.9 and 3.9 months for chemo/immunotherapy, proteasome inhibitor, venetoclax and ncBTKi.”

“Salvage treatment after covalent BTKi failure: An unmet need in clinical practice in Waldenstrom macroglobulinemia”

Authors: Anna Maria Frustaci, Arianna Zappaterra, Andrea Galitzia, Francesco Piazza, Alessandra Tedeschi et al.

More posts featuring Robert Orlowski.

Alessandra Tedeschi Andrea Galitzia Anna Maria Frustaci Arianna Zappaterra cancer Francesco Piazza Myeloma Paper of the Day OncoDaily Oncology Robert Orlowski Waldenström macroglobulinemia

Dr. Manette Le Grange joins OncoDaily Editorial Board

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

New Paper Alert Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience

Highlights from TTLC2025

KIMMTRAK (Tebentafusp) uses in Cancer: Dosages, Indications, Expectations and more